A Randomized, Double-Blind, Parallel-Group Phase III Trial Investigating the Glycemic Efficacy and Safety Profile of Fixed-Dose Combination Dapagliflozin and Linagliptin Over Linagliptin Monotherapy in Patients with Inadequately Controlled Type 2 Diabetes with Metformin

• Published in: Diabetes therapy Vol. 15; no. 1; pp. 215 - 227
• Main Authors: Jain, Aditi, Vispute, Abhay, Dange, Amol, Naskar, Arindam, Mondal, Asish, Vivekanand, B., Sharma, Balram, Varade, Deepak, Shukla, Dhaiwat, Bhatia, Girish, Chaudhari, Harshal, Ram Babu, K., Gavali, Onkar, Sorate, Sanket, Bhanushali, Shaishav, Kothari, Vaibhav, Khandelwal, Vipul, Sharma, Akhilesh, Pawar, Roshan, Mayabhate, Mayur, Shahavi, Vinayaka, Rajput, Aashishsingh, Jaiswal, Mukesh
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01-01-2024; Springer
• Subjects: Cardiology; Dapagliflozin; Diabetes; Drug therapy; Drug therapy, Combination; Endocrinology; Internal Medicine; Linagliptin; Medicine; Medicine & Public Health; Original Research; Patient outcomes; Testing; Type 2 diabetes; India; Glycemic control; Linagliptin; Randomized trial; Metformin; Dapagliflozin; Type 2 diabetes
• ISSN: 1869-6953; 1869-6961
• DOI: 10.1007/s13300-023-01504-3

Introduction
The aim of the study was to evaluate the efficacy and safety of fixed-dose combination (FDC) of dapagliflozin (10 mg) and linagliptin (5 mg) in comparison to linagliptin 5 mg (Trajenta) in patients with insufficiently controlled type 2 diabetes mellitus (T2DM) on metformin monotherapy.
Methods
The double-blind, randomized, multicentric, parallel-group phase III trial screened 287 adult patients with T2DM (age 18–65 years) from 16 sites across India. The recruited subjects were undergoing metformin monotherapy ≥ 1000 mg/day for at least 28 days. Patients with HbA1c of 7.5–10.5% (58–91 mmol/l) (
n
 = 232) after 2 weeks of run-in period with linagliptin monotherapy and placebo dapagliflozin/linagliptin on metformin monotherapy were randomized (1:1) in parallel to once daily dapagliflozin/linagliptin 10/5 mg or linagliptin 5 mg for 16 weeks. Patients were stratified on the basis of HbA1c (≤ 9.0% and > 9.0%; ≤ 75 mmol/l and > 75 mmol/l)). A total of 225 subjects completed 16 weeks of treatment, 115 patients in the test group and 110 patients in the reference group.
Results
Dapagliflozin/linagliptin (
p
 = 0.0003) exhibited a greater change in HbA1c from baseline than linagliptin (
p
 < 0.0001) in 16 weeks (mean reduction, − 1.28% vs − 0.83%). Test group showed a significant decrease in fasting plasma glucose (FPG), postprandial plasma glucose (PPG) and body weight compared to the reference group. The FDC was well tolerated with adverse events being more frequent in the reference group. No serious adverse events (SAEs) were reported in the study.
Conclusion
Dapagliflozin/linagliptin combination is a novel dipeptidyl peptidase 4 (DPP4)/sodium-glucose co-transporter 2 (SGLT2) inhibitor FDC approved in India for patients with T2DM. Potential limitations of this study are a small dose of dapagliflozin (10 mg) in the FDC, a short study duration (30 weeks) and a high minimum threshold for HbA1c (≤ 7.5%; ≤ 53 mmol/l). Results indicate the FDC to be a superior therapeutic option over linagliptin for patients with T2DM on metformin monotherapy.
Trial Registration
CTRI/2022/08/044563; 01/08/2022.